Abstract
Immunotherapy with PD-1/PD-L1 antibody is now the standard of care for the treatment of metastatic non-small cell lung cancer (NSCLC) but many tumors develop PD-1/PD-L1 resistance. We hypothesize based on existing preclinical and clinical data that combining a T-cell agonist such as varlilumab (anti-CD27 antibody) with checkpoint inhibition may be synergistic and this synergy may be potentiated further by using targeted radiation. Targeted radiation improves antigen presentation and immune infiltration and this combination may help overcoming resistance to PD-1/PD-L1 therapies for the treatment of NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
